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BCS1 BCS1LThe bc1 complex or complex III is a central component of the aerobic respiratory chain in prokaryotic and
eukaryotic organisms. It catalyzes the oxidation of quinols and the reduction of cytochrome c, establishing a
proton motive force used to synthesize adenosine triphosphate (ATP) by the F1Fo ATP synthase. In eukaryotes,
the complex III is located in the inner mitochondrial membrane. The genes coding for the complex III have a
dual origin. While cytochrome b is encoded by the mitochondrial genome, all the other subunits are encoded
by the nuclear genome. In this review, we compile an exhaustive list of the known human mutations and asso-
ciated pathologies found in the mitochondrially-encoded cytochrome b gene as well as the fewer mutations in
the nuclear genes coding for the complex III structural subunits and accessory proteins such as BCS1L involved
in the assembly of the complex III. Due to the inherent difﬁculties of studying human biopsy material associated
with complex III dysfunction, we also review the work that has been conducted to study the pathologies with
the easy to handle eukaryotic microorganism, the yeast Saccharomyces cerevisiae. Phenotypes, biochemical data
and possible effects due to the mutations are also discussed in the context of the known three-dimensional
structure of the eukaryotic complex III. This article is part of a Special Issue entitled: Respiratory complex III and
related bc complexes.
© 2012 Elsevier B.V. All rights reserved.1. Introduction
Mitochondria are subcellular compartments present in almost all
eukaryotic cells. Their inner membrane hosts the multi-subunit pro-
tein complexes of the respiratory chain (Fig. 1) that produces the
power (under the form of a transmembrane electrochemical gradient
of protons used for ATP synthesis) required by cells and organisms to
survive. It is assumed that in humans for instance, 90% of the ATP
requirement is provided by the mitochondrial respiratory function.
Mitochondrial function is not restricted to ATP production, in some
cases, there is no ATP synthesis at all, as is found in heat-producing
brown adipose tissues for example [1]. An important mitochondrial
function is also the maintenance of the cellular redox state. This latterP, Rieske or Iron Sulfur Protein;
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l rights reserved.function iswell revealed inmitochondrial disorders forwhich an unbal-
anced NADH/NAD+ ratio and lactic acidosis may be biochemical signs
of the disease. Furthermore it has been shown that mitochondria are
able to store an appreciable amount of calcium [2–4] to modulate calci-
um signals [5–7] and to induce cellular apoptosis [7–9]. In addition,
membrane potential is required by mitochondrial transporters that
facilitate the import into the mitochondria of the numerous proteins
(>1000) synthesized in the cytoplasm. The mitochondria are the site
of major steps of diverse metabolic pathways. They host an essential
central part of carbon central metabolism (TCA cycle, β-oxidation of
fatty acids etc.) in addition to the biosynthesis of the iron–sulphur and
haem prosthetic groups.
According to these numerous essential functions, it is thus under-
standable that any defect in respiratory enzymes caused by genetic
mutation or pharmacological interference may result in disastrous
consequences with a multiplicity of presentations according to the
tissues and the affected function.
A large number of mitochondrial diseases are due to mutations in
the respiratory complexes [10], among which mutations in complex
III (CIII) are not the most frequent in comparison with the numerous
complex I-(ND1-6 genes) or tRNA-associated mutations reported in
the mitochondrial genome. They do, however, present the same
diversity of pathologies compared with mitochondrial mutations in
Fig. 1. Schematics of the mitochondrial respiratory chain and differences between mammalian and yeast S. cerevisiae. Q is quinone (UQ6 in yeast, UQ10 in mammalian), QH2 is
quinol. Brown arrows indicate chemical protons and red arrows indicate pumped protons transported across the membrane during respiratory complex activity. PDB codes are:
1OZK [129] for type II NADH dehydrogenases Ndep1, Ndep2 (external) and Ndip (internal) homology models (in dark green); 2FUG [130] and 3RKO [131] for complex I
(in blue); 3SFE [132] for complex II (in red); 1PP9 [133] for complex III (dimer in magenta and cyan); 1OCR [134] for complex IV (in green); 2B4Z [135] for cyt c (in grey).
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prime importance, particularly to understand the pathologies associ-
ated with mutations in CIII, but also to acquire a better knowledge of
the functioning of this complex in normal conditions.
1.1. Heteroplasmy and the threshold effect: the special case of complex III
Due to the high copy number of mitochondrial DNA (mtDNA)
molecules in a human cell, a mitochondrial mutation might not
necessarily be present in all mtDNA molecules, so that a mixture
of mutated and wild-type mtDNA coexists in the same cell or mito-
chondrion. The percentage of mutated mtDNA, called heteroplasmy
(which is not necessarily the same in all cells and tissues) clearly
plays an important role in the expression of the corresponding mito-
chondrial mutation and the onset of a disease. It rapidly became
apparent that a low proportion (between 5% and 10%) of wild-type
mtDNA could be sufﬁcient to compensate for a much greater propor-
tion of mutated mtDNA [11]. In concordance with this result, it was
observed that a rather high inhibition of a given complex is necessary
to get an appreciable decrease in the rate of oxygen consumption or
ATP synthesis [12]. The plot of the rate of oxygen consumption as a
function of the inhibition of each complex evidences ﬁrst a slight
decrease until a ‘threshold’ after which (high inhibition) the VO2
decreases abruptly.
This process was systematically studied for all complexes in differ-
ent tissues by titrating the activity of each complex with a speciﬁc
inhibitor [13]. The thresholds are different depending on tissues, on
complexes and on the conditions. The study in [13] shows that the
control coefﬁcient of CIII in rat mitochondria respiring on pyruvate
is nearly zero with a high threshold, greater than 80% in all tissues,
except heart (around 60–70%). It means that an 80% decrease in the
CIII activity will appreciably decrease the ATP synthesis in heart and
not in the other tissues. With succinate, a lower threshold is observed
and is different in muscle and liver [14]. The same authors showed
that CIII has a low control coefﬁcient in the measurement of the
II+III activity i.e. that a rather large decrease in CIII activity (under
60%) will not change the succinate-cyt c reductase (CII+III) activity,
so that the measurement of this activity is not a reliable assessment ofa decrease in CIII activity [15,16]. This difﬁculty in assessing a de-
crease in CIII activity and the difﬁculty in measuring directly this
activity is perhaps a reason for which CIII mutations may be difﬁcult
to identify. The existence of a threshold in the expression of a muta-
tion affecting an enzyme activity is not restricted to oxidative phos-
phorylation and respiratory complexes, it is a general response of a
metabolic network to an enzymatic change due to the buffer effect
played by the metabolite intermediates [17].
In addition to heteroplasmy and threshold effects described above,
the detection and analysis of the primary cause of the pathologies
may be complicated by the fact that the respiratory chain complexes
are themselves components of larger structural and functional units,
the respiratory chain supercomplexes or “respirasomes” described
in bacterial as well as in mitochondrial membranes [18]. Repercus-
sions of mutations in cyt b of CIII have been observed in CI activity
in mice and also in patients [19] however it does not seem to be a
general rule since cyt b mutation does not always lead to decreased
CI and -IV activities [20] as reported in the Part 1 below.
1.2. Complex III structure and mechanism:
CIII is a homodimeric complex with a mass of approximately
480 kDa consisting of 10–11 subunits per monomer. Three subunits
form the electron-transferring catalytic core and contain the redox-
active groups; haems and [2Fe2S] cluster, namely cyt b, cyt c1 and
the iron sulphur (or ‘Rieske’) protein (ISP). The atomic structure of
CIII from a variety of organisms has been solved [21–24]. These struc-
tures share the same catalytic core and are very well superimposable
between bacteria and eukaryotes (yeast, chicken and cow). The cen-
tral subunit is cyt b, a predominantly hydrophobic protein consisting
of eight transmembrane helices linked via extramembranous loops. In
eukaryotes, cyt b is mitochondrially encoded while the other subunits
are nuclearly encoded.
CIII catalyzes the transfer of electrons from ubiquinol (CoQH2) to
cytochrome (cyt) c and couples this electron transfer to the vectorial
translocation of protons across the inner mitochondrial membrane.
The enzyme has two discrete quinone-binding sites (Qo or QP, quinol
oxidation site and Qi or QN, quinone reduction site), which are located
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electron-transfer pathway (Fig. 2). Cyt b provides both the Qo and
Qi pockets and the transmembrane electron pathway (via haems bL
and bH).
The catalytic mechanism of CIII is rather complicated and although
the subject of intensive research, it is far from being entirely deciphered
at themolecular level. It is largely accepted that it operates according to
the Q-cycle hypothesis originally proposed by P. Mitchell and modiﬁed
by others (Fig. 2) [25–28]. The two electrons from a CoQH2 molecule,
bound to the so-called Qo site, are not linearly transferred to two cyt c
molecules but take two distinct pathways; only one of these routes
(a high potential pathway) lead to cyt c via the ISP protein, localized
on the external side (the positive side) of the innermitochondrialmem-
brane. The other electron pathway crosses the membrane, taking a low
potential pathway, towards another quinone binding site (Qi located on
the other (negative) side of the membrane). Proton movements across
the inner mitochondrial membrane are associated with these electron
transfers, and thus energy is conserved as an electrochemical proton
gradient. The “Q-cycle” mechanism results in an increased energetic
yield in comparison with a linear pathway. The mechanism responsible
for the electron bifurcation in Qo, which is the basis of the catalytic
mechanism, is still largely unknown at the molecular level.
The study of human CIII variants is rather difﬁcult due to the low
quantity of material available in biopsies and also due to heteroplasmy.
Biochemical assays have been developed for measuring the combined
activities of the different complexes (CI–V) with a limited amount of
biological material from a patient (less than a hundred milligrams),
the CIII activity being measured by the antimycin-sensitive reduction
of cyt c with decylubiquinol as electron donor [29,30]. Yeast
(S. cerevisiae) CIII presents a great advantage since the availability of
biological material is not a limitation in the study. In addition, yeastFig. 2. Complex III catalytic mechanism. Only the three catalytic subunits (cyt b in blue, Riesk
oxidising and reducing sites, respectively. PDB code: 3CX5 [109] (yeast CIII cocrystalized wmitochondria are homoplasmic for a given mitochondrial mutation.
The yeast CIII is very similar to the human enzyme with 50% identity
for cyt b. Human mutations of CIII can be introduced in yeast and their
effect on the complex assembly and activity can be analyzed in details.
When the respiratory defect caused by the mutation is severe, the
yeast models of human disease mutations can be used to investigate
compensatory mechanisms, giving hints for possible treatment.
It must be stressed that the composition in respiratory complexes
of the respiratory chain is similar in yeast and human (Fig. 1) with the
exception of a multisubunit, protonmotive CI (complex I, NADH-
ubiquinone oxidoreductase) which is absent in S. cerevisiae and
replaced by three type II NADH dehydrogenases (Fig. 1). One (Ndip)
is directed to the matrix [31] and the two other (Nde1p and Nde2p)
to the intermembrane space [32,33]. The absence of CI in yeast rein-
forces the role of yeast CIII in building the proton-motive force.
In this review, we will analyze the numerous mutations associated
with human pathologies not only related to the mitochondrial encoded
cyt b but also the fewer mutations in genes coding for the supernumer-
ary subunits of the CIII (subunits 7 and 8) and the accessory proteins
(BCS1L, TTC19) necessary for the CIII biogenesis, all encoded by the
nuclear genome. As noted above, the yeast S. cerevisiae is a very useful
model to study human pathologies and we will also describe the muta-
tions introduced in the S. cerevisiae cyt b gene to mimic the human
pathologies. Results are discussed in the context of the available atomic
structures of the yeast and vertebrate CIII.
1.3. Part 1: Human mutations leading to a pathology directly related to
the complex III
Most of the mutations found in genes coding for the membrane-
bound complexes of the mitochondrial respiratory chain in mane protein in red and cyt c1 in green) and cyt c (in grey) are shown. Qo and Qi are quinol
ith cyt c). See text for details on the catalytic mechanism.
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which codes for the subunits ND1-6 of CI (NADH:ubiquinone oxidore-
ductase), cyt b in CIII (bc1 or ubiquinol cyt c reductase), subunits 1–3
of CIV (cyt c oxidase) and also for the ATPase subunits 6 and 8. Rela-
tively fewmutations are associated with the nuclearly-encoded genes
of the respiratory complexes. This is due to the difﬁculties into iden-
tifying such mutations in the whole nuclear genome and to the lower
rate of appearance of nuclear genome mutations in comparison with
the mitochondrial genome [34]. The reasons for the latter are two-
fold: ﬁrstly, the mitochondrial DNA is more exposed to reactive
oxygen species (ROS) produced by the respiratory chain and hence
suffers a higher degree of oxidative damage, and secondly, the DNA
repair system is less efﬁcient in mitochondria. Along with CI, CIII is
a main site of ROS production and at high level, they damage cellular
components and can induce cell death and are assumed to be involved in
aging processes. Studies ofmitochondrial genomes in human population
revealed polymorphisms (supposedly neutral), which have been used as
phylogenetic tools to investigate human origins and migrations. Several
reports have pointed out the possible impact of haplogroups (mtDNA
lineages sharing common polymorphisms) onmitochondrial physiology
(for instance on aging, adaptation to colder climate, susceptibility to
other mitochondrial mutations). Some haplogroup-speciﬁc polymor-
phisms are located in cyt b, the central catalytic subunit of CIII.
1.3.1. Mutations in the mitochondrial encoded cytochrome b
The review of all cyt bmutations described in the literature [35,36]
and presented herein reveals a few common features. Firstly, it
appears that skeletal muscle involvement, exercise intolerance and
lactic acidosis are often reported in the pathologies. However, we
should stress that these characteristics are not speciﬁc and not always
encountered in cyt b defects and thus cannot constitute a rule for the
detection of cyt b mutations linked to pathologies. Almost all the cyt
b mutations are heteroplasmic and often detected in skeletal muscle
tissue, with fewer in other tissues leading to the proposal that the
mutations arose de novo after differentiation of the primary germ
layers in cases where the mutations are not maternally inherited.
An alternative explanation proposed in [37] is that sporadic muta-
tions would segregate preferentially in muscle tissues and less in
other tissues due to a negative selection.
Due to the heterogeneity of the pathologies linked to the cyt b
mutations as seen in Table 1 (exercise intolerance, cardiomyopathy,
deafness, LHON, MELAS, etc.), it is rather difﬁcult to gather together
classes of mutations and their different effects in human. We thus
describe each important mutation and its associated effects in the
next section which is divided in two paragraphs; the ﬁrst paragraph
describes the single mutations which are more likely responsible for a
pathology and the second reports the cyt b mutations possibly linked
to diseases and associated with other mutations (often in ND1 in case
of LHON pathology) present in the mitochondrial genome.
1.3.1.1. Cytochromebmutations involved in the primary cause of pathologies.
In the human population, the cyt b gene (MTCYTB) exhibits a high level
of variance. Over 100 missense changes from the consensus reference
sequence (the rCRS, revised Cambridge Reference Sequence) have been
reported (mitomap.org). Most of these variations might be silent. How-
ever, some variations, especially those located in regions involved in the
catalytic activity might induce subtle changes in CIII function that are
unnoticed during normal circumstances. In certain adverse conditions,
these changes might affect the cell ﬁtness and subsequently the health
of the individuals bearing these variants. Mutations in cyt b have also
been associated with mitochondrial diseases or reported in patients
with speciﬁc cancers (see below).
Cyt b is encoded between nucleotides 14747 and 15887 on the
heavy strand of the mtDNA [38]. The MTCYB gene in humans does
not contain introns which is in contrast to yeast [39]. The gene
codes for a highly hydrophobic polypeptide of mass 42.7 kDawhich migrates anomalously during SDS-PAGE with an apparent
mass of 30 kDa due to the presence of eight transmembrane helices
(Fig. 3).
In 1970, before the sequence of human mitochondrial cyt b was
available, Spiro et al. [40] described the ﬁrst study of cyt-related
inherited disorder. Two cases were studied, a 46 year-old man and his
16 year-old son affected with muscle weakness, progressive ataxia,
dementia and nervous system disorder. A decreased cyt b content was
measured in muscle mitochondria. Later Morgan-Hughes et al. [41]
reported a patient with myoclonus followed by generalized weakness,
ataxia, andmental confusion. Biochemical studies onmusclemitochon-
dria revealed a defect at the cyt b level. A patient reported by
Darley-Usmar et al. [42] showed tissues speciﬁc defects found in associ-
ationwith lactic acidosis andmuscularweakness. Biopsies revealed low
CIII activity and low level of reducible cyt bwith diminished quantity of
core proteins, ISP and subunit VI. The possible role of cyt b as the site of
the primary defect was proposed.
In 1984, Hayes et al. [43] reported a 20 year-old Chilean girl who
presented with ptosis and fatigable weakness. A high proportion of
the muscle ﬁbres contained aggregations of abnormal mitochondria
and biochemical investigation demonstrated a respiratory chain deﬁ-
ciency localized to CIII. Birch-Machin et al. [44] reported a newborn
infant with severe lactic acidosis and CIII deﬁciency in skeletal mus-
cles and liver mitochondria. The issue was fatal after 3 days.
When sequencing of mitochondrial DNA became relatively routine
during the 1990s, mutations could be identiﬁed at the molecular
level. Bouzidi et al. [45] described a low CIII activity in muscle from
a 25 year-old man with progressive exercise intolerance and later
Dumoulin et al. [46] identiﬁed the ﬁrst cyt b missense mutation
shown to be pathogenic, changing the conserved Gly290 in Asp (see
Table 1, Fig. 3, and Part 2 for yeast phenotype).
Andreu et al. [47] described 5 patients (from 32 to 52-year-old)
with progressive exercise intolerance, lactic acidosis, in some cases
myoglobinuria and biochemical evidence of CIII deﬁciency. They identi-
ﬁed three nonsensemutations (p.Trp113Ter, p.Trp141Ter, p.Trp326Ter),
onemissensemutation in the cyt b gene leading to the p.Gly34Ser substi-
tution and a deletion of 8 residues p.Gly251_Leu258del (Table 1, Figs. 3, 4
and see Part 2). There was no maternal inheritance and there were no
mutations in tissues other than muscle. Andreu et al. [47] concluded
that there is sporadic form of mitochondrial myopathy and the disorder
is due to somatic mutations in myogenic stem cells after germ-layer
differentiation.
The same research group [48] described a 38 year-old female
patient who developed progressive muscle weakness with exercise
intolerance and elevated arterial lactate. The family history was neg-
ative for neuromuscular disorders. A heteroplasmic (85% of the total
mitochondrial DNA) cyt b mutation in the patient's muscle was iden-
tiﬁed and corresponds to substitution p.Gly339Glu (Table 1, Fig. 3 and
see Part 2).
Andreu et al. [49] described also an infant girl with multisystem
disorder (including hepatic steatosis and kidney tubular necrosis).
She was the ﬁrst case described with histiocytoid cardiomyopathy
and died of cardiac arrest at the age of 4 weeks. The authors identiﬁed
a heteroplasmic mutation in cyt b gene resulting in a p.Gly251Asp
substitution (Table 1, Fig. 3 and see Part 2).
Keightley et al. [37] reinvestigated a 34-year-old woman followed
for 17 years, originally reported in [50], with symptoms of lactic aci-
dosis and exercise intolerance associated with severe CIII deﬁciency.
She responded to therapy with menadione and ascorbate. Gradually,
she developed a mitochondrial encephalomyopathy. Keightley et al.
[37] identiﬁed a nonsense mutation resulting in a truncated cyt b
(p.Gly166Ter, Table 1). The heteroplasmic mutation was present at
87% in skeletal muscle and only 0.7% in blood. The mutation was
also present in other tissues, including hair roots, indicating that it
must have arisen either very early in embryogenesis or in the mater-
nal germline.
Table 1
Human mutations leading to pathology and a possible dysfunctional complex III.
Mutations in
mitochondrial
encoded cyt b
Mitochondrial
nucleotide
change
Mutation in human Causing diseases or associated with
symptoms/polymorphism
Residue in
yeast/mutation
Depicted
in Fig. 3
References
14787del I14-frameshift MELAS/Parkinsonism V13 [52,53]
C14792G H16D Associated with ND6, Leigh syndrome S15 [68]
G14831A A29T LHON, ND1 associated/polym. Y28 [69]
A14841G N32S LHON, ND1 associated N31 [70]
G14846A G34S Exercise intolerance G33S + [47]
T14849C S35P Optic dysplasia, exercise intolerance, cardiomyopathy S34 + [55]
T14864C C40R MELAS C39 + [63]
G15024A C93Y Possible deaf helper mutation V92 [71]
G15043A G99-synonymous Associated with Major Depressive Disorder/polym. A98 [72]
G15059A G105Ter Exercise intolerance and myoglobinuria G104 [121]
G15077A E111K DEAF associated/polym. T112 [73]
G15084A W113Ter Exercise intolerance W114 [47]
G15150A W135Ter Exercise intolerance Y136 [58]
G15168A W141Ter Exercise intolerance W142 [47]
G15170A G142Ter Exercise intolerance, lactic acidosis G143 [59]
T15197C S151P Exercise intolerance S152P + [58]
G15242A G166Ter Encephalomyopathy G167 [37]
G15243A G166E Cardiomyopathy G167E + [51]
G15257A D171N LHON associated factor/polym. S172 [66,67]
T15287C F181L Possible deaf factor/polym. L182 [74]
A15395G K217E LHON associated factor R218 [75]
C15452A L236I Cardiomyopathy/polym. M237 [51,122]
G15497A G251S Obesity, exercise intolerance/polym. G252 [123,124]
G15498A G251D Cardiomyopathy,deafness/polym. G252D + [49,76]
15498del24 G251DPDNYTL-del Exercise intolerance G252HPDNYIP-del + [47]
A15533G N263D Lactic acidosis, seizures, mental delay; possibly
associated with unknown nuclear mutation
V264 [64]
A15579G Y278C Multisystem disorder Y279C + [54]
G15615A G290D Exercise intolerance G291D + [46,125]
T15621G L292R Possible LHON helper mutation I293 [126]
T15635C S297P Neonatal polyvisceral failure A298 + [20]
T15635G S297A Possible LHON helper mutation A298 [126]
A15662G I306V Multi-disorder mitochondriopathy/polym. F307 [77]
T15674C S310P LHON/polym. S311 [78]
T15693C M316T Cardiomyopathy, possible left ventricular
noncompaction/polym.
T317 [79]
G15699C R318P Exercise intolerance, encephalopathy K319P + [60]
G15723A W326Ter Exercise intolerance F327 [47]
G15761A G339Ter Exercise intolerance G340 [61]
G15762A G339E Mitochondrial myopathy, exercise intolerance G340E + [48]
G15773A V343M Possibly synergistic, associated with LHON/polym. V344 [80]
C15800T Q352Ter Exercise intolerance, myopathy Q353 [62]
G15812A V356M Synergistic, associated with LHON/polym. F357 [66,77]
Mutations in nuclear
genes coding for
CIII subunits
Gene/Function/
Locus
Mutation in human Disease Equivalent
in yeast
Depicted
in Fig. 3
References
UQCRB/Subunit 7
13.5 kD/8q22.1
Change the last seven
a.a. and addition of
14 a.a. at C-ter.
Hypoglycemia, CIII activity deﬁciency Qcr7/Subunit 7
14.5 kD
+ [85]
UQCRQ/Subunit 8
9.9 kD/5q31.1
S45F Severe neurologic defects a.a. Q55 in Qcr8/
Subunit 8 10.9 kD
+ [86]
Mutations in nuclear
genes coding for
biogenesis factors
Gene/Function/
Locus
Mutation in human Disease Mutation in yeast
(human numbering)/
Yeast
complementation
see
Fig. 5
References
BCS1L/CIII-FeS
subunit assembly
factor/2q35
G35R
R45C
T50A
Leigh, GRACILE or Bjornstad syndromes,
Encephalopathy, hepatic failure and tubulopathy,
muscle weakness, optic atrophy.
G35Ra
S78Ga
P99La
[94–97,
100–105,127]
R56Ter R114Wa
R73C R155Pa
S78G R183Ha
P99L R184Ca
I106Ter R291Tera
R114W Q302Ea
G129R R306Ha
R144Q P99Lb
R155P R155Pb
R183H, C S277Nb
R184C V353Mb
S277N K192Pc
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Fig. 3. Disease-associated mutations within cytochrome b and the Qcr7, 8 subunits of the complex III. This ﬁgure was prepared using the coordinates for yeast (S. cerevisiae) CIII
(3CX5.PDB, [109]). Represented in cartoon form are CIII subunits cyt b (green), Qcr7 (grey) and Qcr8 (purple). A glass van der Waals surface has been added to cyt b to aid visual
clarity. Residues associated with human disease mutations are shown for cyt b (except nonsense mutations leading to a truncated cyt b) and Qcr8 using yeast notation, with the
corresponding human residues given in parentheses. The seven-residue deletion ΔGly251-Leu258 at the Qo site is represented in blue cartoon form. The seven-residue addition
to the C-terminus of Qcr7 (μ7) is indicated in yellow. Also shown are Qo-bound stigmatellin (orange), cyt b haems bL and bH (red), cyt b-bound 3-SN-phosphatidylethanolamine
(8PE in pink) and the [2Fe2S] cluster from Rieske ISP protein (polypeptide backbone not shown). Refer to Table 1 and text for more details.
Table 1 (continued)
Mutations in nuclear
genes coding for
biogenesis factors
Gene/Function/
Locus
Mutation in human Disease Mutation in yeast
(human numbering)/
Yeast complementation
see
Fig. 5
References
R291Ter S314Nc
Q302E R73Cd
R306H R183Cd
V327A R184Cd
V353M F368Id
F368I F368I+R73Cd
G129Re
TTC19/FeS CIII
assembly, only
metazoan/17p12
Q173Ter
L219Ter
Neurodegenerative disorder,
CIII activity decreased in muscle
Ortholog unknown [108]
The list of cyt b mutations is derived from MITOMAP (A Human Mitochondrial Genome Database. http://www.mitomap.org, 2011) and updated. We used the HGVS (Human
Genome Variation Society) nomenclature in the text but for space and clarity reasons, we use a simpler nomenclature in the Tables and Figures.
Abbreviations: DEAF: Maternally inherited DEAFness or aminoglycoside-induced DEAFness; GRACILE: Growth Retardation, Amino aciduria, Cholestasis, Iron overload, Lactic acidosis
and Early death; LHON: Leber Hereditary Optic Neuropathy. MELAS: Mitochondrial Encephalomyopathy, Lactic Acidosis and Stroke-like episodes; polym.: reported as polymorphism
in the MITOMAP data base (http://www.mitomap.org/bin/view.pl/MITOMAP/PolymorphismsCoding).
a Yeast ΔBCS1 complemented by the human BCS1L containing the mutations [94].
b Yeast ΔBCS1 complemented by the human BCS1L gene containing mutations [95].
c Yeast ΔBCS1 complemented by the yeast BCS1 gene containing mutations [95].
d Yeast ΔBCS1 complemented by the human BCS1L gene containing mutations [100].
e Yeast ΔBCS1 complemented by the human BCS1L gene containing mutation [105].
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Fig. 4. Yeast cytochrome bmutations and associated reversions studied as models for human pathologies. This ﬁgure was prepared using S. cerevisiae CIII coordinates 3CX5.PDB. The
polypeptide backbone of cyt b is represented in green with the Rieske ISP in grey. Residues associated with human pathologies upon mutation are shown with yellow labels (yeast
notation). Suppressor mutations (reversions) are indicated with blue labels. Also shown are stigmatellin (orange), cyt b haems bL and bH (red) and the ISP [2Fe2S] cluster. Refer to
Table 2 and text for more details.
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novo cyt b mutation leading to the substitution p.Gly166Glu (Table 1,
Figs. 3, 4 and see Part 2) in one patient with severe hypertrophic
cardiomyopathy. It is noteworthy that out of the ﬁve isolated patients
with CIII deﬁciency, only one carried a cyt b mutation and this study
supports an autosomal rather than a maternal inheritance in the
majority of their patients with CIII deﬁciency [51].
De Coo et al. [52] identiﬁed a heteroplasmic 4-bp deletion leading
to a truncated protein (p.Ile14fs, Table 1). The young boy patient had
an akinetic rigid syndrome and a mitochondrial encephalomyopathy
with lactic acidosis and stroke-like episodes (MELAS). He developed
parkinsonism and myoclonus. More than 95% of the mtDNA in muscle
was mutated. Rana et al. [53] found defective synthesis of the cyt b
protein, decreased amount of ISP and subunit VI, defective oxidative
phosphorylation, defective CIII activity and increased hydrogen peroxide
production, indicative of increased electron transfer bypass reactions to
oxygen.
Wibrand et al. [54] described a patient who, besides severe exercise
intolerance, had also multisystem disorder (deafness, mental retarda-
tion, retinitis pigmentosa, cataract, growth retardation, epilepsy) with
a selective decrease of CIII activity in muscle. The heteroplasmic muta-
tion in muscle (88%) and leukocytes (15%) changed a highly conserved
Tyr to Cys at position 278 (Table 1, Figs. 3, 4 and see Part 2).
Schuelke et al. [55] described a 25-year-old patientwith neurologic
symptoms starting in infancy. He suffered from septo-optic dysplasia,retinitis pigmentosa, exercise intolerance, hypertrophic cardiomyopa-
thy. The mutation m.14849T>C was heteroplasmic in muscle (69%)
and ﬁbroblasts (12%) resulting in the p.Ser35Pro substitution within
cyt b (Table 1, Fig. 3). Analysis of this p.Ser35Pro substitution in the
atomic structure of the bovine CIII in the presence of the Qi site sub-
strate quinone (1NTZ.pdb [56]) shows that residue Ser35 is located
in transmembrane helix A on the Qi site and is only 4.5 Å from the sub-
strate ubiquinone hydrophobic tail and in close proximity (4–5 Å) to
the edge of haem bL. Substitution of a Ser by a Pro likely distorts this
transmembrane helix and interferes with ubiquinone and/or haem
binding. Such mutation was not reported in any other organism (see
for review [57]) and could be easily studied in yeast in order to better
understand the cyt b defects at a molecular level.
Legros et al. [58] reported two original deleterious mutations
(substitutions p.Trp135Ter and p.Ser151Pro, see Table 1, Figs. 3, 4
and Part 2). The heteroplasmic mutations were only found in muscle
tissue where they represented 60–80% of the mtDNA molecules. Both
patients had an intolerance to exercise from their late childhood with
a CIII activity below 20% in muscle associated with a reduced amount
of cyt b protein but activity was found normal in leukocytes and
ﬁbroblasts.
Bruno et al. [59] described a 40-year-oldwomandevelopingprogres-
sive exercise intolerance, lactic acidosis andmuscle cramps beginning at
the age of 30 years. Histochemical and biochemical studies revealed
ragged-red cyt c oxidase positive ﬁbers and combined deﬁciency of CI
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codon (p.Gly142Ter, Table 1). The mutation was very abundant in mus-
cle (>90%) but undetectable in lymphocytes and ﬁbroblasts.
A p.Arg318Pro substitution of a highly conserved amino acid was
reported in a 38-year-old woman suffering from migraine, muscle
pain, sensorineural deafness [60] associated with a severe reduction
in the activities of both CI and CIII in skeletal muscle. (Table 1,
Figs. 3, 4 and part 2).
Mancuso et al. [61] reported the cyt bm.15761G>A heteroplasmic
mutation (73% in muscle) leading to a stop codon (cyt b p.Gly339Ter,
Table 1) and thus a truncated protein with a loss of the last 41 resi-
dues corresponding to the gh loop and the last transmembrane
helix H. The 19-year-old woman suffered from exercise intolerance,
vomiting and lactic acidosis.
Another truncated cyt b protein with the subsequent loss of
transmembrane helix H was also reported in [62] with the cyt b non-
sense mutationm.15800C>T (substitution p.Gln352Ter). The affected
24-year-old woman had exercise intolerance with muscle cramps and
lactic acidosis. The mutation was heteroplasmic in muscle (45%) but
absent in the other tissues examined. This mutation is associated
with a combined deﬁciency in CI and CIII activities.
Recently, Emmanuele et al. [63] described a novel mutation
m.14864T>C in MTCYB (a.a. change p.Cys40Arg, Table 1 and Fig. 3)
in a 15-year-old girl affected with migraines, epilepsy, sensorimotor
neuropathy, and stroke-like episodes (MELAS). The mutation was
heteroplasmic in muscle, blood, ﬁbroblasts, but absent in her asymp-
tomatic mother. Residue Cys40 is highly conserved and located in the
middle of transmembrane helix A, between haems bL and bH. Muta-
tion to the much larger and cationic Arg residue is likely to be delete-
rious to the correct folding and (thermodynamically unfavorable)
insertion of helix A into the hydrophobic interior of the lipid bilayer.
All the cyt bmutations described above are found to beheteroplasmic.
However, Fragaki et al. [20] described an unusual fatalmultisystemic pre-
sentation and the ﬁrst case of a homoplasmic mutation m.15635T>C
in all tissues tested leading to the replacement of a conserved Ser297
into Pro (Table 1 and Fig. 3). The patient was a new born boy died at
24 h of age of polyvisceral failure. Since her mother did not exhibit any
mutation, the mutation is supposed to have arisen de novo very early in
embryogenesis. A CIII activity deﬁciency was detected but other respira-
tory chain complex (CI, CII, CIV) and ATPase activities were unaffected.
Ser297 is located in the middle of transmembrane helix F and replace-
ment with a bulkier Pro could distort the local environnement of helix F
and likely modiﬁes drastically the overall cyt b folding.
1.3.1.2. Cytochrome b mutations associated with other mitochondrial
mutations. A number of mutations in cyt b may not be the primary
cause of humandisease but are associatedwith othermutations present
in either mitochondrial genes (for example in the LHON pathology) or
rarely in nuclear genes [64]. These type of mutations described below
are reported in Table 1 but are not depicted in Fig. 3 if the direct involve-
ment of these mutations in pathology is not demonstrated but they
mainly act as secondary and helper mutations or can be deﬁned later
as polymorphisms.
LHON (Leber Hereditary Optic Neuropathy) is a maternally-
inherited form of acute visual loss and blindness. Two major cyt b
alleles have been described to contribute to LHON pathology. The
ﬁrst substitution (p.Asp171Asn) (Table 1) is located in a hydrophilic
region at the end of the amphipathic cd2 helix, at less than 10 Å
from the ISP protein. Substitution p.Asp171Asn may possibly affect
the docking of the ISP with cyt b during the catalytic cycle. Substitu-
tion p.Asp171Asn was found to be pathogenetically signiﬁcant but
was not found alone associated with LHON [65]. The m.15257G>A
mutation (p.Asp171Asn) is always associated with mutations in the
mitochondrially encoded ND5 [66,67] or ND6 genes of CI. The second
cyt b mutation corresponds to substitution p.Val356Met associated
with the primary LHON mutations in ND5 and ND6 subunits of CI orassociated together with the cyt b p.Asp171Asn substitution de-
scribed above [66,67]. Val356 (Phe357 in yeast, see Table 1) is located
in the transmembrane helix H and its side chain is facing outside the
CIII towards the membrane bilayer and away from interdimeric con-
tacts, so it is difﬁcult to predict the possible repercussions of this sec-
ondary mutation on the function of CIII. For these two reported cases
of cyt bmutations associated to the LHON pathology, the involvement
of both CI and CIII mutations indicates that the clinical signs might be
the consequences of the synergetic effects of mutations and an overall
decrease in mitochondrial energy production. However, these two cyt
b substitutions (p.Asp171Asn and p.Val356Met) are now reported as
polymorphisms in the Mitomap database. In this case of multiple mu-
tations, yeast may provide an excellent model since it is homoplasmic
for a given mitochondrial DNA mutation and thus can be used to
study the effects of each individual mutation. This could reveal that
a given mutation leads to a real phenotype or has no effect and is
more likely a polymorphism.
Cyt b p.His16Asp substitution (Table 1) was reported by Ronchi et
al. [68] in addition to mutation in ND6 leading to a Leigh syndrome in
a 15-month-old female patient but to date this mutation does not
seem to be associated with pathology since the mother, homoplasmic
for the cyt b mutation, was not affected by the pathology. Residue
His16 (Ser15 in yeast) is located with loop a in the amino terminal
region of cyt b in the matrix side.
Fauser et al. [69] found in LHON patients the m.15257G>A muta-
tion (cyt b change p.Asp171Asn) already reported in LHON patholo-
gies (see above) and described a novel mutation m.14831G>A (cyt
b change p.Ala29Thr, Table 1) but the real pathogenicity of this muta-
tion was not proven since it is associated with a second ND1mutation
and a 16S rRNA polymorphism. Residue Ala29 is located at the begin-
ning of the transmembrane helix A in the Qi site.
Yang et al. [70] reported on a Chinese family carrying the novel
heteroplasmic m.14841A>Gmutation (cyt b replacement p.Asn32Ser,
Table 1) and affected by the LHON pathology with visual impairment.
The authors suggest that this mutation may play a synergistic role
with a ND1 mutation, increasing the severity of the LHON pathology.
Residue Asn32 is located 6 Å from both the Qi site quinone molecule
and a propionate of haem bH on the negative side of the membrane,
at the amino-terminal region of the transmembrane helix A.
Tang et al. [71] described a case of maternally hearing loss in a
Chinese 16-year-old man. The primary mutation is m.7505T>C in
tRNASer but the mutation m.15024G>A leading to the cyt b substitu-
tion p.Cys93Tyr (Table 1) may have a modifying role in deafness ex-
pression. Residue Cys93 lies in the middle of transmembrane helix B
and substitution with the larger Tyr side chain introduces a steric hin-
drance with proximal residues.
In a study related to the Major Depressive Disorder, Rollins et al.
[72] reported a m.15043G>A mutation (not changing the nature of
cyt b residue Gly99) associated with two others mutations in mitDNA,
a putative haplotype associated with risks factors for psychiatric dis-
orders. The cyt b mutation is reported as a polymorphism (Mitomap
database).
Lévêque et al. [73] reported a maternal inherited m.15077G>A
mutation (cyt b substitution p.Glu111Lys) as one of the putative path-
ogenic variants in hearing impairment (polymorphism in Mitomap
database).
Ballana et al. [74] have identiﬁed a three-generation family segre-
gating two heteroplasmic mtDNA mutations: the deafness-related
m.1555A>G mutation in the 12S rRNA gene and a new mutation
m.15287T>C (substitution p.Phe181Leu) in the cyt b gene. Phe181
is located in the Qo region, in transmembrane helix D and at the
interdimeric interface with the trans dimeric cyt bmolecule. Mutation
to Leu may thus be disruptive for the stable association of the dimer,
although a Leu residue is naturally present in the corresponding yeast
position (Leu182, Table 1) and this mutation may be a polymorphism
(Mitomap database).
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ied in [75]. In addition to a ND4 and others mitDNA mutations, the
cyt b m.15395A>G mutation (substitution p.Lys217Glu, Table 1)
may act synergistically with the primary LHON mutation. Lys217 is
located in the cyt b de loop, on the matrix side at the interface with
subunit 8 of the CIII. Introduction of a negatively charged Glu instead
of the positively charged Lys could destabilize the interaction be-
tween cyt b and Subunit 8.
Sensorineural hearing loss is one of the most frequent clinical
features in patients with mitochondrial diseases caused by mutations
in mitDNA. Kato et al. [76] reported a m.15498G>A mutation (substi-
tution p.Gly251Asp, Table 1, Figs. 3, 4 and Part 2) possibly linked to
deafness. This mutation was already encountered in a case of cardio-
myopathy [49].
An interesting study [64] reported on a patient affected with
seizures, lactic acidosis, mental delay and behavior abnormalities
associated with a decrease in CIII activity in patient's skeletal muscle.
Mutant (m.15533A>G leading to cyt b change p.Asn263Asp, Table 1)
transmitochondrial cybrids restored normal activities and the proband's
mother, clinically unaffected, also harbored the homoplasmic mutation.
These results demonstrate the possible pitfalls in the detection of path-
ogenic mitochondrial mutations, and highlight the role of the genetic
mtDNA background in the development of mitochondrial disorders.
This case raises the possibility of a primary unknown nuclear mutation
responsible for the disease and the lower CIII activity.
Finsterer et al. [77] studied the case of a 33-year-oldmanwithmajor
renal insufﬁciency and severe multi-disorder mitochondriopathy. One
novel heteroplasmic mutation m.15662A>G (>75% in skeletal muscle)
was detected (cyt b substitution p.Ile306Val, Table 1) in addition tomu-
tations in ND1 gene and the cyt bmutation m.15812G>A (substitution
p.Val356Met already observed in LHON [66]). Ile306 residue is located
at the C-terminal region of transmembrane helix F, facing the solvent
on the matrix side of the complex. Mutation to Val is a conservative
change, but could be deleterious for the interaction with the nearby
helix bc loop. It should mentioned that the patient did not exhibit any
alteration in CIII activity. The residue Ile306 is not conserved during
evolution and the corresponding mutation m.15662A>G is reported
as a polymorphism in the Mitomap database but the cumulative effects
of the four transitions in the mitochondrial DNA are not excluded to
explain the pathology.
Abu-Amero et al. [78] investigated a 16-year-old patient with
LHON and reported a m.15674T>C mutation (cyt b substitution
p.Ser310Pro, Table 1) in addition to a pathogenic mutation in the
tRNAGln. The cyt bmutation is reported to be pathogenic but one can-
not exclude the primary role of the tRNAGln mutation. Residue Ser310
is located in the fg loop, on the negative side of the membrane and
mutation to a Pro residue seems compatible without any drastic
changes in this cyt b region, however an unpredicted detrimental ef-
fect is not excluded, perhaps mediated by perturbed interaction with
nearby subunit Qcr7.
Tang et al. [79] were looking for mitochondrialmutations associated
with the heart left ventricular noncompaction condition. They de-
scribed a 16-year-old patient with left ventricular trabeculation associ-
ated with the rare mutation m.15693T>C (substitution p.Met316Thr,
Table 1) which could be potentially pathogenic, however this mutation
is reported as a polymorphism (Mitomap database). Met316 residue is
located in the cyt b fg loop on the negative side of the membrane. As
with the S310P variant, mutation of Met316 to Thr may affect the
local fold of the fg loop leading to destabilisation of the interaction
with nearby Qcr7.
A possible secondary role for the cyt b p.Val343Met substitution
(mutation cyt b m.15773G>A, Table 1) was reported [80] in Italian
patients with LHON pathology and myoclonus. Two homoplasmic
LHON mutations in ND4 and ND1 genes were present in these
patients. Results suggest that the LHON phenotype may relate to the
synergic role of the mtDNA variants. Val343 is located in the gh loopon the positive side of the membrane. Simulating the p.Val343Met
substitution in the atomic structure of CIII does not seem to indicate
a particular steric hindrance or electrostatic interaction with proximal
residues and this mutation is reported as a polymorphism (Mitomap
database).
1.3.2. Somatic cytochrome b mutations
Finally, several acquired somatic mitochondrial mutations (not
shown in Table 1) have been found in cancer pathologies, including
homoplasmic mutations. For example, Fliss et al. [81] reported a
21-bp deletion at nucleotide 15642 (corresponding to human cyt b
residues p.Leu299_Pro305del) in a patient with bladder cancer.
This region of cyt b is located in the transmembrane helix F and this
deletion is likely to be severely deleterious to the fold of cyt b and
by consequence the assembly of the intact CIII.
In a colorectal cancer, Polyak et al. [82] found 3 somatic mutations
in the mitochondrial genome. Two occurred in the cyt b gene leading
to p.Arg80His or p.Phe276Leu substitutions and one mutation in the
COXI gene. Arg80 is located at 3.5 Å from the propionates of haem
bL in the CIII 3D-structure and mutation with the positively charged
side-chain of His could modify the properties of haem bL. Phe276
(Pro277 in yeast) is located in the ef loop just after the P270EWY273
motif conserved through evolution and important for catalysis of
quinol substrate in the Qo site.
A likely cause for the accumulation of mitochondrial mutations in
cancer cells is the production of ROS in this organelle by the respira-
tory chain. ROS oxidatively damage the rapidly mutiplying mtDNA
molecules and this is coupled with the lower level of DNA repair in
mitochondria compared to the nucleus [83]. These ﬁndings suggested
that mitochondrial mutations may contribute to tumor growth as
pointed out early on by Warburg [84] who suggested that alterations
of oxidative phosphorylation in tumor cells play a causative role in
cancerous growth.
1.3.3. Mutations in the nuclear encoded structural subunits of the
complex III
To our knowledge, only two nuclear genes coding for intrinsic CIII
subunits have been reported to contain mutations in human and lead
to a pathology. The ﬁrst report in 2003 by Haut et al. [85] described
the case of a young Turkish girl born of consanguineous parents
(both healthy and heterozygous for the mutation) with a homozy-
gous 4 bp deletion in exon 4 of the UQCRB gene located in chromo-
some 8. The deletion is predicted to change the last seven amino
acids and to add a stretch of 14 residues at the C-terminal region of
the subunit 7 of 13.5 KD (Table 1 and Fig. 3). This C-terminal region
of subunit 7 is accessible from the outside of the CIII (Fig. 3) and is
in contact with Core protein I of the trans monomer in the CIII dimeric
structure, on the matrix side of the membrane. The patient suffered
from hypoglycemia and liver dysfunction associated with a CIII
activity deﬁciency and a lower amount of cyt b as determined
spectrophotometrically.
The second case was reported by Barel et al. [86] with a consan-
guineous Israeli Bedouin kindred presenting an autosomal-recessive
phenotype with severe psychomotor retardation, dystonia, ataxia
and marked dementia. Reduced CI and III activities were found in
muscles. A single homozygous missense mutation (p.Ser45Phe) in
UQCRQ (encoding CIII subunit VIII in chromosome 5) was detected
and is shown in Fig. 3 to be localized in the Qi site region, facing cyt
b and a phosphoethanolamine molecule which is located 4 Å from
the Ser45 side chain in the yeast CIII atomic structure. The introduced
bulky Phe residue may destabilize interactions with this lipid mole-
cule which could modify the conformation of this region important
for catalysis on the Qi site, as it has already been observed for the
importance of lipid molecules in the CIII [87]. Note that in the closest
relative to human CIII 3D-structure, the bovine CIII 3D-structure (pdb
2A06) displays also this phosphoethanolamine molecule in the same
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activities found in patients.
1.3.4. Mutations in the nuclear encoded auxiliar subunits required for the
complex III assembly
The synthesis and assembly of the respiratory chain complexes is a
rather complicated process (especially in eukaryotes), requiring addi-
tional proteins encoded by the nuclear genome and imported into the
mitochondrion. There are as many as thirty different factors involved
in the assembly process of yeast CIV (cyt c oxidase) [88]. To date,
thirteen different factors have been described and reviewed in [89]
speciﬁc for the CIII assembly in yeast, namely Cbs1, Cbs2, Cbp1 and
Cbp3 as translational activators of COB mRNA, Cbp2 as a splicing fac-
tor of COB pre-mRNA, Cbp4 and Cbp6 interact with the newly synthe-
sized cyt b, Cyc2 is involved in the cyt c and c1 maturation process,
Cyt2 as haem lyase for cyt c1, Bca1 a recently discovered factor for
early step in CIII assembly [90], Mzm1 a matrix protein for the ISP
protein assembly [91], TTC19 a membrane protein only found in
metazoans and Bcs1 an AAA-ATPase necessary for the ISP insertion.
To date, only the latter two nuclear genes, BCS1L and TTC19, were
shown in man to contain mutations which lead to pathologies. How-
ever most of the CIII deﬁcient cases remain to be elucidated at the
molecular level. It is likely that more mutations in already known as-
sembly factors will be described as well as in yet unknown assembly
factors which remain to be discovered.
1.3.4.1. The case of BCS1L. Bcs1 was initially identiﬁed by Tzagoloff
et al. [92] as a inner membrane protein necessary for yeast respiratory
growth. The human BCS1L gene encodes a homolog of S. cerevisiae
BCS1 gene involved in the assembly of CIII. BCS1 is present in all
eukaryotes but not in bacteria. The Bcs1 protein shares sequence sim-
ilarity with members of the AAA-ATPases superfamily. The predicted
419-amino-acid human protein is 50% identical to the yeast Bcs1.
Bcs1 is a translocase of the FeS subunit of the CIII across the inner
membrane and is involved in its topogenesis rather than a chaperone
protein. Bcs1 is a membrane-bound protein with one transmembrane
helix (Fig. 5) and its AAA-domain is facing the matrix side where Bcs1
and the ISP subunit may interact. Bcs1 is likely to form an oligomeric
ring structure (often hexameric for other AAA-ATPases) with a cen-
tral pore in the membrane necessary to translocate ISP, a reaction
requiring ATP hydrolysis (see for review [93]).
More than 20 different mutations have been mapped on the BCS1L
gene [94] and linked to human diseases (Table 1 and Fig. 5). The ﬁrst
mutations found in the BCS1L gene were described by de Lonlay et al.
[95] who reported six patients from four different families of Turkish
origin with CIII deﬁciency. Two patients and one foetus had mutation
leading to the p.Ser277Asn transition. The pathologies of the patients
were neonatal tubulopathy, hepatic failure, and encephalopathy. Two
other unrelated patients from consanguineous families had acidosis,
hepatic failure and neurologic symptoms, consistent with a LeighG35R
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Fig. 5. Amino-acid changes leading to pathologies in the human BCS1L. Schematic representation
helix (a.a. 16–32); MTS: Mitochondrial Targeting Signal; AAA-ATPase domain of the AAA type fa
Finger (Arg343–Arg346). Amino-acid substitutions alone or in combination (see text and Tablesyndrome: the mutation caused the substitution p.Pro99Leu (Table 1,
Fig. 5). A ﬁfth newborn patient had two mutations in BCS1L leading to
both p.Arg155Pro and p.Val353Met substitutions. Yeast complementa-
tion studieswith the yeast or human gene containing the corresponding
mutations (Table 1) conﬁrmed the deleterious effects of thesemissense
mutations [95].
The GRACILE syndrome (Growth Retardation, Amino aciduria,
Cholestasis, Iron overload, Lactic acidosis and Early death) affected
Finnish patients with the BCS1L homozygous mutation leading to
the substitution p.Ser78Gly [96] (Table 1, Fig. 5). Contrary to the
Turkish patients described above, the Finnish patients had normal
CIII activity and no neurological problems. However they exhibited
marked hepatic iron overload. This high level of free plasma iron
could arise from the loss of the [2Fe2S] cluster from the ISP. Visapää
et al. [96] also described three British infants who had a different
pathology with CIII deﬁciency and neurological symptoms. They are
associated with BCS1Lmutations leading to substitutions p.Val327Ala,
p.Arg56Ter, p.Ser78Gly, p.Arg144Gln as well as mutations in the
introns splicing sites.
Very recently, Lynn et al. [97] described a male infant who died at
three months of age and presenting with GRACILE-like syndrome. He
was affected with acidosis, hypoglycaemia, aminoaciduria and iron
overload but had no neurological symptoms. A strong defect in CIII
activity was detected and to a lesser extent at the level of CI and
CIV. Both the nonsense mutation c.166C>T leading to substitution
p.Arg56Ter and inherited from the father and the c.-588T>Amutation
in the 5′ untranslated ﬁrst intron region upstream from the start
codon and inherited from themother, were already reported in British
infants described above [96].
A mouse model carrying a homozygous mutation leading to the
substitution p.Ser78Gly describedbyde Lonlay et al. [95]wasdeveloped
recently and represents the ﬁrst example of viable higher eukaryotic
model of CIII deﬁciency mimicking a human mitochondrial disorder of
nuclear origin [98]. The mouse model exhibits similar symptoms with
the human patients.
Bjornstad syndrome is the least severe disease associated to BCS1L
mutations. It is an autosomal recessive disease characterized by
sensorineural hearing loss and pili torti (ﬂattened and twisted hair
shafts). Lubianca et al. associated the Bjornstad syndrome with the
locus 2q34-36 [99]. Hinson et al. [94] identiﬁed mutations in BCS1L
resulting in p.Arg183His substitution in eight related individuals
from consanguineous parents. In a four-year-old child, Hinson et al.
[94] described a Bjornstad syndrome with mild mitochondrial CIII
deﬁciency and found heterozygosity for 2 missense mutations leading
to substitutions p.Arg184Cys and p.Gly35Arg (Table 1 and Fig. 5). Five
additional BCS1L sequence variants were identiﬁed: one affected a
splice site (leading to a truncated protein I106Ter), one lead to a truncat-
ed protein (p.Arg291Ter) and three missense mutations (p.Arg114Trp,
p.Gln302Glu, p.Arg306His) in combination (or not)with the substitution
p.Arg306His found in the case of Norwegian ancestry. All BCS1LAAA-ATPase
R291TerS277N
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R306H V327A V353M
F368I
419220
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of the human BCS1L protein (a.a. 1–419)with the different domains: TM: TransMembrane
mily proteins (a.a. 220–419) including the Walker A motif (a.a. 230–237) and the Arginine
1 for more details) and causing a pathology in human are indicated by an arrow.
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and the clinical severity of the mutations was also correlated with the
production of reactive oxygen species.
Fernandez-Vizarra et al. [100] reported two isolated cases of
young patients heterozygous for two mutations in BSC1L. The ﬁrst
case was a Moroccan girl with encephalopathy, lactic acidosis, psy-
chomotor regression, hypotonia, deafness, brittle hair and CIII activity
deﬁciency. Although the parents were unrelated, two proximal muta-
tions were present in BCS1L, one mutation was inherited from the
mother (substitution p.Arg184Cys, Table 1, Fig. 5) and one from the
father (substitution p.Arg183Cys). Studies with yeast model showed
that both individual mutations reduced mitochondrial respiratory
activity and affect the incorporation of ISP in the CIII. The second
case was an Italian girl from healthy unrelated parents, deceased at
four-year-old. Her pathologies were encephalopathy, lactic acidosis,
psychomotor delay, hypotonia, seizures, failure to thrive, brittle hair
and CIII activity deﬁciency. Two mutations were detected in the
BCS1L gene and lead to the substitutions p.Arg73Cys and p.Phe368Ile
(Table 1 and Fig. 5). Introduction of themutations in yeast S. cerevisiae
lead to the conclusion that the replacement p.Phe368Ile is more detri-
mental than p.Arg73Cys.
De Meirleir et al. [101] investigated two Spanish patients that died
prior to the age of three months. They had lactic acidosis, severe fail-
ure to thrive, liver dysfunction, renal tubulopathy and accumulation
of iron in aggregates of macrophages which could be explained by
the lack of incorporation of iron into the [2Fe\2S] cluster of ISP
protein. An isolated biochemical CIII deﬁciency was detected in
liver. Sequencing BCS1L gene revealed a missense mutation leading
to substitution p.Arg45Cys and a nonsense mutation p.Arg56Ter
(Table 1, Fig. 5). Each parent was heterozygous for one of the muta-
tions. The missense mutation in combination with an absence of
BCS1L function due to the second allele is responsible for the CIII
deﬁciency in this family.
Ramos-Arroyo et al. [102] reported another Spanish infant carrying
the substitutions p.Arg45Cys and p.Arg56Ter in BCS1L. Her symptoms
were neonatal severe hypotonia and food intolerance and she devel-
oped lactic acidosis, renal tubulopathy with glucosuria and aminoacid-
uria. At the age of four months, she showed nystagmus, microcephaly
and hypertonia prior to death at the age of six months. Muscle tissue
exhibited impaired CIII activity. This child did not show iron overload
as previously observed in patients reported in [101] and as has been
observed in GRACILE syndrome described above. Ramos-Arroyo et al.
[102] proposed that phenotypic variability in individuals with the
same BCS1L mutations in a nuclear gene may be related to the tissue
speciﬁcity of the expression of the mutant gene.
Blázquez et al. [103] described an infantile encephalomyopathy
with unusual phenotype in a 4-year-old Spanish boy affected with
different symptoms such as psychomotor retardation, dysmorphic
features, failure to thrive, hypotonia, lactic acidosis, mild sensorineu-
ral hearing loss and hepatic dysfunction. However iron metabolism,
renal function and hair were normal. Mitochondrial CIII deﬁciency
was detected in muscles and ﬁbroblasts associated with lower
amounts of both BCS1L protein and CIII. They identiﬁed a homozy-
gous mutation in BCS1L gene resulting in a p.Thr50Ala substitution
in the mitochondrial targeting signal (Table 1, Fig. 5). Each unaffected
parent was heterozygous for the mutation.
Morán et al. [104] studied ﬁbroblasts from six CIII-deﬁcient
patients harboring mutations in the BCS1L gene (corresponding
to isolated or combined substitutions p.Pro99Leu, p.Arg56Ter,
p.Arg45Cys, p.Arg184Cys, p.Thr50Ala, Table 1 and Fig. 5). Cells
exhibited slow growth in glucose, increased H2O2 levels, variable
enzyme deﬁciencies and assembly defects of CIII but also of CI and
CIV. Apoptotic cell death, structural alterations such as abnormal
mitochondrial morphologies and fragmentation of the mitochondri-
al networks were also described in patient's ﬁbroblasts. The patients
had cytosolic accumulation of the BCS1L protein, suggestive of animpaired mitochondrial import, assembly or stability defects of the
BCS1L complex.
A 20-year-old Kenyan woman patient was described by Tuppen
et al. [105]. She was a ‘ﬂoppy’ infant whose condition worsened dur-
ing childhood with increasing muscle weakness and optic atrophy.
A CIII deﬁciency due to a homozygous BCS1L mutation leading to
the substitution p.Gly129Arg (Table 1, Fig. 5) was demonstrated.
The yeast S. cerevisiae carrying the human BCS1L substitution
p.Gly129Arg is not able to grow on respiratory substrates.
1.3.4.1.1. Yeast as a model for BCS1 studies. In addition to be a very
useful model for studying pathologies of mitochondrial origin (see
part 2), yeast offers also the opportunity to mimic human pathologies
of nuclear origin.
The two following studies have been carried out in the yeast
S. cerevisiae to better understand the function of Bcs1 and more
precisely the role of speciﬁc residues, some of them implicated in
changes leading to pathologies in human. The use of yeast points
out similarities but also differences between the yeast and human
Bcs1 due to the fact that the same mutations do not always produce
the same phenotype and biochemical results as seen below.
Conte et al. [106] reported in yeast S. cerevisiae that the gradual
expression of Bcs1 leads to the formation of supercomplexes CIII–IV.
The yeast substitution p.Arg81Cys allows CIII and supercomplex
assembly in yeast whereas the corresponding human p.Arg45Cys
substitution (Table 1 and Fig. 5) was instead the cause of a severe
CIII deﬁciency [101]. However, yeast variants p.Lys192Pro and
p.Phe401Ile (corresponding to human p.Arg155Pro and p.Phe368Ile
substitutions associated with diseases, Table 1 and Fig. 5) severely
altered the CIII structure and activity.
Using yeast, Nouet et al. [107] have performed a structure–function
analysis of Bcs1 by randomly generating a collection of respiratory-
deﬁcient mutants. They showed that most mutations are in the
C-terminal region of Bcs1. Intragenic and extragenic compensatorymu-
tationswere isolated. They showed that residues located at the junction
between the Bcs1-speciﬁc and the AAA domains are important for the
activity and stability of the protein and that the yeast residue Phe342
is important for interactions with partners or substrate proteins.
1.3.4.2. Gene TTC19. The second gene recently described and involved
in assembly of CIII which carries human mutations is TTC19 encoding
for the tetratricopeptide repeat domain 19 (with 5 TPR domains
mediating protein–protein interactions) of 45.5 kDa (mature size
35 kDa). It is located in the mitochondrial inner membrane and has
been shown to physically interact with CIII. This protein is present
in all metazoan but absent in other eukaryotes (plants, fungi) and
prokaryotes. TTC19 gene contains at least 10 exons and is encoded
by chromosome 17 in human.
Ghezzi et al. [108] identiﬁed in two 37 and 24-year-old siblings
from north-eastern Italy a homozygous mutation in the TTC19
gene resulting in a p.Leu219Ter substitution truncating the protein
(Table 1). They had a slowly progressive neurodegenerative disorder
with onset in late infancy. A third unrelated subject from the same
alpine area had a similar disease course. Muscle biopsies showed a
marked isolated reduction of mitochondrial CIII activity. In addition,
the authors identiﬁed a man with adult-onset mitochondrial CIII
deﬁciency with a different homozygous mutation in the TTC19 gene
resulting in a p.Gln173Ter substitution (Table 1). The patient was clin-
ically normal until 42 years old and then rapidly developedprogressive
neurological failure and died 3 years later. Muscle biopsy showed
marked CIII deﬁciency. Ghezzi et al. [108] reported also the knockdown
of the ﬂy (Drosophilia) TTC19 ortholog which resulted in reduced life
span, low fertility and locomotor impairment in the adult ﬂy.
The proposed function for the mitochondrial targeted TTC19 pro-
tein is a chaperone involved in the early step of CIII assembly but
questions remain regarding its direct function in interaction with
Table 2
Yeast cytochrome b mutations studied as model for human pathologies (see Fig. 4).
Mutations Respiratory
growth
Complex III
level
(%WT)
Complex III
activity
(%WT)
Suppressor
mutations
References
G33S Deﬁcient 55 12 None [111]
S152P Deﬁcient 55 6 ISP A90D [111]
G167E Deﬁcient 75 22 E167+W164L
E167+W166L
[113]
Δ252–259 Deﬁcient 60 0 None [111]
G252D Competent 90 100 [111]
Y279C Weak growth 75 58 [111]
G291D Deﬁcient 50 11 D291+D287h
D291+H53D
ISP V88A/G/D
ISP A90T/D
[111]
K319P Deﬁcient 50 50 [60]
G340E Deﬁcient Decreased 0 Deletion of E340
E340A
E340V
E340+C342G
E340+E345G
E340+K288N
[117,128]
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activity in the TTC19 null mutant in Drosophila melanogaster larvae,
and the relatively late-disease onset in patients. This suggests age
and tissue dependent regulation of TTC19 [108].
1.4. Part 2: Use of the yeast model to study cytochrome b mutations
associated with human disease
A number of mutations in the human cyt b have been linked with
diseases in man (Table 1, Fig. 3). Nonsense or frameshift mutations
that result in truncated cyt b almost invariably abolish complex
assembly. The precise effect of the missense mutations is often
more difﬁcult to predict or determine. Their characterisation in
human tissues or cells is frequently hampered by the limited amount
of tissue available and by the lack of cell lines harboring the mutation
to be studied. The yeast S. cerevisiae is a convenient model for such a
study as it has well-known advantages. Cells can survive in the
absence of respiration by using the fermentation process as an energy
source. Therefore the absence of one or more respiratory enzymes is
not lethal. The yeast bc1 complex (and especially the catalytic core)
is very similar to its counterpart in humans. The atomic structure of
the yeast enzyme has been determined [23,109,110]. Many genetic,
biochemical and genomic tools are available. Of particular interest
for such study, is the mitochondrial transformation technique.
Using that method, engineered mutations can be introduced into
mitochondrially-encoded genes, such as the cyt b gene. The mutants
are then analyzed by a broad range of methods.
Using that approach, the impacts of human diseases were ana-
lyzed to determine the effects at the structural andmechanistic levels,
and to explore possible compensation mechanisms. From respiratory
growth deﬁcient mutants, respiratory competent clones could be se-
lected and the secondary mutations (suppressors or compensatory
mutations) identiﬁed.
1.4.1. Mutations in the Qi site region and perturbation of the overall bc1
complex assembly
p.Gly33Ser. Gly33 is located within transmembrane helix A, a
hydrophobic environment at the Qi site, close to haem bH. The intro-
duction of a Ser chain of the mutation p.Gly33Ser could perturb the
local environment of the haem. The mutation had severe effect on
the bc1 structure as it was observed that the level of cyt b was de-
creased by 50%, spectral properties of cyt b were altered and the
level of ISP was dramatically lowered, which was likely to result
from a major perturbation of cyt b folding (Table 2, Fig. 4) [111].
p.Lys319Pro. Arg319 is very highly conserved in the vertebrate,
plant and bacterial sequence data. It is replaced by Lys in fungi. Arg/
Lys319 is located at the C-terminal region, a β-turn linking helices
F2 and G and probably acts as a backbone H-bond donor to Asp316.
Mutation of p.Lys319Pro would remove this H-bond and may disrupt
the geometry of the turn. As judged by the lower bc1 content in mu-
tant cells, the mutation hampers the assembly of the complex [60]
(Table 2, Fig. 4).
1.4.2. Mutations and compensatory mutations in the Qo site region of
cytochrome b
p.Ser152Pro: Ser152 is located at the entrance of the Qo site, at the
C-terminal end of helix cd1, immediately preceding a β-turn leading
to helix cd2 and may be hydrogen-bonded to Lys288 located at the
P-side of helix F1 (Fig. 4). Mutation to Ala results in a marked resis-
tance to atovaquone associated with loss of function as the bc1 com-
plex activity was decreased to 20% of wild type control [112].
p.Ser152Ala has no major effect on the enzyme assembly but would
result in the loss of H-bonding capacity, which could result in slight
structural rearrangement of the Qo pocket, a decreased afﬁnity of
atovaquone for the site and a lessened catalytic activity. Mutation to
Pro had more severe effect and results in the loss of the ISP fromthe bc1 complex and a nearly inactive enzyme (Table 2) [111]. The
introduction of a Pro might be expected to distort the local fold of
the region between cd1 and cd2, which is in close proximity with
the [2Fe2S] domain of the ISP when this subunit is docked in the
b-‘proximal’ position. Such a change is likely to be deleterious to the
stability of the complex.
p.Gly167Glu: Gly167 is located in the extramembranous cd2 helix
of cyt b. The residue is in close proximity of residues forming the ﬂex-
ible ‘tether’ of the ISP, a region essential for the macroscopic move-
ment of the cluster-containing headgroup of the subunit. Gly167 is
highly conserved between organisms. It may be that a Gly at this po-
sition is required for the proper folding of the hinge region. It seems
likely that replacement of Gly167 by the bulkier and charged residue
could interfere with the movement of the ISP, which would in turn
alter the catalytic activity of the complex. The mutation could also
affect the binding of the ISP to the bc1 complex. Experimental data
showed that the mutation had severe effect on the bc1 complex
activity and that the mutant enzyme was sensitive to detergent and
unstable in assay conditions. It was suggested that the ISP was pro-
gressively lost during the assay or its assembly was progressively
distorted causing further inhibition of the enzyme activity [113].
The bc1 complex activity was partially restored by mutations located
close to the primary mutation, p.Trp164Leu and p.Trp166Leu, which
are likely to reduce the steric hindrance caused by p.Gly167Glu
(Table 2, Fig. 4).
p.Gly252_Pro259del: The deletion of eight amino acids may be
expected to severely disrupt the assembly of the complex (Table 2,
Fig. 4). However the mutant enzyme was still partially assembled,
as judged by the optical signal for cyt b but the level of ISP was dra-
matically decreased [111]. The mutation is located in a surface loop
connecting helices E and ef loop on the P side of the membrane, and
is not directly in contact with the ISP. The alteration of the folding
of cyt b caused by the shortening of this loop is likely to disrupt the
stable binding of the ISP. The small population of ISP-containing en-
zyme was inactive. This could be explained by the major alteration
of the catalytic site caused by the deletion.
p.Gly252Asp: The mutation p.Gly252Asp had no effect on yeast
growth or bc1 activity under standard conditions (Table 2). It has been
reported that the yeast p.Gly252Asp mutant was thermosensitive, as
the mutant bc1 complex was found to be partly inhibited when the
cells were grown at higher temperature (36 °C) [114]. Examination of
the yeast bc1 3D-structure (1P84.pdb [110]) reveals a tightly-bound
phospholipid molecule at the P-side interface between cyt b and c1.
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side-chains of His185 of cyt c1 and Ser268 of cyt b, with the fatty acyl
chains in hydrophobic contact with Trp273. An additional hydrogen
bond is provided by the imidazole ring of His253 (cyt b) to an acyl
ester oxygen atom of the bound lipid. Mutation p.Gly252Asp may dis-
rupt this latter hydrogen bonding association, or distort the local fold
at the lipid–protein interface. The possible interference of Asp252
with structural lipid could, in consequence, destabilize the enzyme
assembly under some conditions.
p.Tyr279Cys: Tyr279 is in close proximity to the highly conserved
‘P271EWY274’ motif region at the N-terminal region of the ef helix and
within 3.5 Å of residue His181, a ligand of the ISP [2Fe\2S] cluster.
The mutation p.Tyr279Cys has a moderate effect on the respiratory
growth competence, little effect on bc1 complex level and does not
hinder the stable binding of the ISP (Table 2, Fig. 4). p.Tyr279Cys
affects the quinol binding as EPR spectra showed an altered signal
indicative of a lower occupancy of the Qo site [111]. The positioning
of ubiquinol at the Qo site has been suggested to be inﬂuenced by
hydrogen bonding interactions with the side-chain hydroxyl group
of Tyr279 [110]. Interestingly, the same change is responsible for
acquired resistance to atovaquone in the malaria agent, Plasmodium
falciparum (p.Tyr268Cys, in P. falciparum). In yeast, p.Tyr279Cys
causes also high level of atovaquone resistance [115]. The equivalent
mutation in R. capsulatus bc1 (p.Tyr302Cys) is associated with ROS
production, intra-subunit crosslinking between the ISP and cyt b,
and [2Fe\2S] cluster damage [116].
p.Gly291Asp: Gly291 is located in a transmembrane helix F1
(Fig. 4), a region of the molecule in the close vicinity of the Qo site.
Replacing Gly by Asp in that hydrophobic environment is likely to
have severe consequence and to impair the folding of cyt b at the Qo
site, hindering the assembly of the ISP into the complex. The bc1 com-
plex level was indeed decreased (Table 2) and the level of ISP was
dramatically lowered [111]. The respiratory function is partially re-
stored by a second mutation in cyt b, p.Asp287His. Residue Asp287
is located in the Qo region, 3 Å from the primary mutation. It is likely
that the replacement of Asp by His reduces the electrostatic repulsion
introduced by p.Gly291Asp and restores a correct folding in the Qo re-
gion. A long-distance compensatory mutation in cyt bwas also found:
p.His53Asp. His53 is located in the loop connecting helices A and ab
near the hinge region of the ISP (the ISP which reacts with the
other monomer). Mutation to Asp may increase the stability of bind-
ing of the ISP to the complex.
p.Gly340Glu. Gly340 is located in the C-terminus of the trans-
membrane helix G, in close proximity to the Qo site (Fig. 4). The res-
idue is located within a predominantly hydrophobic pocket. The
introduction of a charged Glu is expected to be destabilizing. Indeed
the mutation completely abolishes the assembly of the bc1 complex
(Table 2). Removal of the anionic side-chain by the secondary muta-
tions p.Glu340Ala, p.Glu340Val or by the in-frame deletion of
Glu340 restores the respiratory growth competence. Second-site
suppressor mutations were also observed that partially compensate
for the deleterious primary mutation: p.Cys342Gly, p.Glu345Gly and
p.Lys288Asn (Table 2) [117]. These second mutations might remove
some source of destabilising electrostatic and/or steric hindrance
around Glu340.
1.4.3. Compensatory mutations in the Rieske Iron Sulphur protein
Interestingly, other compensatory mutations partially restoring
the bc1 complex function altered by p.Ser152Pro and p.Gly291Asp
were found in the hinge region of the ISP. The [2Fe\2S] prosthetic
group of the ISP is located within its soluble C-terminal domain, on
the P-side of the inner mitochondrial membrane (Fig. 4). This domain
is connected to the transmembrane helix via a ﬂexible hinge region
(sequence T85ADVLAMAK93 in S. cerevisiae) that makes that the
movement of the prosthetic group domain possible. This ISP hinge
region is a “hot-spot” for selecting secondary mutations restoringcyt b Qo site deﬁciency [118]. Several compensatory mutations at res-
idues V88 and A90 were observed (ISP p.Val88Ala/Gly/Asp and
p.Ala90Thr/Asp). The secondary mutations restored a more stable
binding of the ISP on the mutated bc1 complex. However the catalytic
activity was still low.
Suppressor analysis was extended to another cyt b mutant,
p.Ala144Phe. Ala144 is located in helix cd1. p.Ala144Phe results in
an assembled but partially inactive enzyme with altered quinol bind-
ing, which was presumably caused by minor changes in the local
structure of cd1 helix in the Qo site. Several suppressors were found
in the hinge region of ISP between residues 85 and 92 [119]. It was
shown that ISP mutations at residues 85, 92 and 93 compensated
p.Ala144Phe, but not p.Ser152Pro and p.Gly291Asp. It was suggested
these ISP mutations altered the structure of the hinge region and
allowed a greater reach of the ISP [2Fe\2S] domain and a more efﬁ-
cient docking on the Qo site distorted by p.Ala144Phe. From the sup-
pressor analysis, it could be suggested that the hinge region would
play a role in the stabilization of the subunit on the complex and in
a correct positioning of the [2Fe2S] domain on cyt b for an optimal
Qo site catalysis.2. Concluding remarks
As shown in Table 1, most of the human mutations present in CIII
and biogenesis factors are found in the mitochondrial encoded cyt b
(both on the Qo and Qi sites, Fig. 3) which is the catalytic core of the
enzyme and in the accessory factor BCS1L encoded by the nuclear
genome. It is interesting to note the total absence to date of mutations
in the nuclear genes encoding the ISP and cyt c1 that are essential for
the electron transfer activity in the bc1 complex, in comparison with
more than 20 mutations reported in BSC1L gene. It is predicted that
in the future, more mutations present in the nuclear genes encoding
subunits of the bc1 complex will be described and studied in mam-
mals as well as in yeast which is an experimentally tractable and
reliable model for human pathologies as exempliﬁed by several stud-
ies reported here. Our compilation of data in this review may moti-
vate additional biochemical and genetics studies carried out in
S. cerevisiae (or other model organisms like the yeast Yarrowia
lipolytica used for the study of human CI-related pathologies [120])
in order to mimic defects found in human pathologies which would
be otherwise difﬁcult to study at a molecular level using human tissue
samples. The unicellular eukaryotic yeast presents the advantages of
a fermentative growth in case of respiratory deﬁcient mutants, the
unlimited amount of biological material available for study, the
homoplasmic nature of the mitochondrial mutations introduced
by the biolistic method, the in-depth biochemical and biophysical
study of the effects of each mutation. In addition, yeast allows the
study of the repercussions of combined and individual mutation in
the mitochondrial genome in case where multiple mutations are
present in human pathology for example in LHON. Due to the difﬁcul-
ty to localize and detect nuclear mutations in comparison with the
relatively more simple sequencing of the entire mitochondrial ge-
nome, it is also predictable that more mutations will be discovered
in the future in nuclear encoded accessory factors necessary for the
import, correct folding, insertion of metal cofactors and incorporation
of the CIII subunits in the ﬁnal and active membrane complex. Also,
interest in mitochondria and the somatic mutations detected in the
mitochondrial genome with regard to cancer has revived due to
their role in apoptosis and other aspects of tumor biology which are
extensively studied these days.Acknowledgements
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